Wainua Trial Setback Sends Ionis Plunging and Drags Down AstraZeneca

AstraZeneca and Ionis’s Wainua missed its primary endpoint in the Phase 3 ATTR-CM trial, while competitors Alnylam and BridgeBio surged.